The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update-Reference-Cited by-同舟云学术

The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update

Published:2021-01-02 Issue:1 Volume:6 Page:19-29
ISSN:2380-8993
Container-title:Expert Review of Precision Medicine and Drug Development
language:en
Short-container-title:Expert Review of Precision Medicine and Drug Development

Author:

McClure Erin¹,Patel Ayushi¹,Carr Michael J.²^ORCID,Sun James²³,Zager Jonathan S.¹²^ORCID

Affiliation:

1. University of South Florida Morsani College of Medicine, Tampa, Florida, USA

2. Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA

3. Department of Surgery, University Hospitals, Cleveland Medical Center, Cleveland, Ohio, USA

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/23808993.2021.1847639

Reference75 articles.

1. Cancer statistics, 2020

2. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

3. Evidence-based treatment of early-stage melanoma

4. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes;Frontiers in Oncology;2022-04-14

2. Computational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes;2022-01-23

3. Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines;Cancers;2021-12-01